《Current Evidence and Considerations in the Management of Complicated Infections》.pptVIP

下载本文档

0
0
约3.15千字
约 39页
2017-04-25 发布于浙江
举报
版权申诉

《Current Evidence and Considerations in the Management of Complicated Infections》.ppt

1、本文档共39页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital Hartford, CT ;Disclosures;Improving the Probability of Positive Outcomes;Antimicrobial Resistance;Characteristics of Infections due to ESBL-producing BacteriaRisk Factors;Antimicrobial Resistance in Gram-negative bacilli;Clinical Economic Impact of Resistance;Improving the Probability of Positive Outcomes;Antimicrobial Stewardship: Part of the Solution?;Matches antibiotic susceptibilities of the organism to the antibiotic used “S” = Success;Optimizing Antimicrobial Exposures: Pharmacodynamics;Carbapenem Usage Continues to Rise Dramatically in the US (2003-2008);Collateral Damage v. Collateral Benefit;Carbapenem-resistant Enterobacteriaceae (CRE);Acinetobacter baumannii ;Polymyxins ;Expanded broad spectrum of in vitro activity Avoidance of tetracycline-resistance mechanisms;Tigecycline;Log10 Number of organisms;Tigecycline: In Vivo Bactericidal Activity;Tigecycline;Tigecycline Is Not Affected by Common Antibiotic-Resistance Mechanisms;Tigecycline Susceptibility versus ESBL producing Escherichia coli and Klebsiella pneumoniae;Tigecycline: An Expanded Broad Spectrum of In Vitro Activity;Tigecycline Dosing;Clinical Cure Rates in cSSSI and cIAI;Cure Rates by Mono/Polymicrobial Infection in the ME Population in cIAI;Common Treatment-Emergent Adverse Events in cSSSI Studies;Treatment Discontinuation Rates Due to Adverse Events in the m-ITT Population in cSSSI Studies;Complicated Skin skin Structure Gram-positive coverage Vancomycin Linezolid Daptomycin Nafcillin or cefazolin (documented MSSA) Plus Gram-negative coverage Cephalosporins / aztreonam Fluoroquinolones / Aminoglycosides Piperacillin/tazobactam Carbapenems Monotherapy (including MRSA) Tigecycline;Pharmacodynamic Profiles of Agents used in the Management of cSSSI;Tigecycline: Concentration-time Profiles in Plasma Tissue of Patients with Lower Limb Infections;Intraabdominal Infecti